Clinical and preclinical studies demonstrate that T:E fusion is detected in premalignant prostatic intraepithial neoplasia (PIN) lesions [9] and targeted in vivo expression of ERG can induce PIN lesions in transgenic mouse prostate [14], suggesting that ERG plays a casual role in prostate cancer initiation. The gene discussed is ERG; the disease is prostate carcinoma.